Asia-Pacific Migraine Drug Market Research Report - Segmented By Treatment, Therapeutic Class & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC)- Industry Analysis, Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 3953
Pages: 148

APAC Migraine Drug Market Size (2022 to 2027)

As per the research report, the Asia-Pacific Migraine Drug Market size has been calculated at USD 0.76 billion in 2022. It is estimated to be growing at a CAGR of 5.51% and worth USD 0.99 billion by 2027.

Migraine is a typical headache that occurs due to both nerves and blood vessels' involvement, mostly seen more in women than in men. There are two kinds of medications used to treat migraines, in which some are for the cure, and others are for prevention.

The increased prevalence of migraine among people, the growing population, and the growing need for high-quality medicines are majorly driving the APAC migraine drugs market. However, migraines are more common in women than in males. As a result, the expanding female population is a huge advantage for migraine medicines sales. 

In addition, the increased knowledge among the patients about migraine prevention and treatment is the significant factor that enables the migraine drug market growth.

Furthermore, factors such as rising work pressure, high alcohol use, expanding demand for high-quality drugs, changes in lifestyles, and increased patient awareness of migraine prevention and treatment are influencing the demand for migraine drugs. 

Moreover, rising pharmaceutical research and development spending, rising healthcare spending, and a high prevalence of migraines are likely to propel the APAC migraine drugs market forward throughout the forecast period.

On the other hand, the market demand is boosted by rising awareness of the availability of various migraine treatment procedures in rural areas. As a result, market participants and other companies spend in creating new drugs, which helps to level the market's growth rate. Changes in people's lifestyles and increased stress levels are also contributing to the market growth.

However, the market is hampered by the adverse effects of pharmaceuticals and the growing importance of other therapies. Furthermore, the government's stringent laws and regulations are slowing market growth. 

This research report on the Asia-Pacific Migraine Drugs Market has been segmented and sub-segmented into the following categories:

By Treatment: 

  • Preventive
  • Absorptive

By Therapeutic Class: 

  • Triptants
  • Ergots
  • Others

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The APAC Migraine drugs market is projected to account for the highest share during the forecast period. The market growth is fueled by improving healthcare infrastructure, increasing healthcare spending, and favorable reimbursement policies. In addition, the high incidence rate of migraine and growing collaboration and partnership programs in the pharmaceutical sector, Asia Pacific also captures a significant market share in the migraine market. Greater access to healthcare facilities and higher investment by market participants, particularly in emerging countries, are projected to propel the Asia Pacific to rapid growth and increasing market size. The countries in the region such as China, Japan, South Korea, India, Australia, and the rest of the Asia Pacific are contributing to the Asia Pacific migraine drugs market.

India and China are the major countries that contribute to the APAC migraine drugs market in this area.

China accounted for the largest share of the Asia-pacific migraine drugs market over the forecast period, and it is most likely to augment the predominant share in the coming years. The pharmaceutical sector is one of the country's main industries; China is leading the Asia Pacific migraine treatment market with increasing investors. Focus on organic growth, changes in disposable income and rising urbanization are all major variables influencing the market. Furthermore, the sudden outbreak of COVID-19 would cause people to become stressed due to the implementation of the lockdown measures, increasing their risk of migraine and, as a result, predicted to drive the growth of the migraine market in the coming years. 

Some of the companies dominating the APAC Migraine Drug Market profiled in the report are Allergan, GlaxoSmithKline, Pfizer, Endo, Impax Laboratories. The other prominent vendors in the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories,  OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan,  and Zogenix.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample